Hepatitis B Virus e Antigen Activates the Suppressor of Cytokine Signaling 2 to Repress Interferon Action

[1]  J. Christensen,et al.  Suppressors of Cytokine Signaling 1 and 3 Are Upregulated in Brain Resident Cells in Response to Virus-Induced Inflammation of the Central Nervous System via at Least Two Distinctive Pathways , 2014, Journal of Virology.

[2]  S. Kent,et al.  Downregulation of Interleukin-18-Mediated Cell Signaling and Interferon Gamma Expression by the Hepatitis B Virus e Antigen , 2014, Journal of Virology.

[3]  M. Fälth,et al.  Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. , 2014, Gastroenterology.

[4]  Hong Tang,et al.  Correlation between the suppressor of cytokine signaling-1 and 3 and hepatitis B virus: possible roles in the resistance to interferon treatment , 2014, Virology Journal.

[5]  Jianguo Wu,et al.  IL-27, a Cytokine, and IFN-λ1, a Type III IFN, Are Coordinated To Regulate Virus Replication through Type I IFN , 2014, The Journal of Immunology.

[6]  Hong Tang,et al.  Correlation between the suppressor of cytokine signaling-1 and 3 and hepatitis B virus: possible roles in the resistance to interferon treatment , 2014, Virology Journal.

[7]  Mengji Lu,et al.  Hepatitis B virus polymerase impairs interferon‐α–induced STA T activation through inhibition of importin‐α5 and protein kinase C‐δ , 2013, Hepatology.

[8]  Wenhui Li,et al.  Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus , 2012, eLife.

[9]  C. Aspord,et al.  Plasmacytoid dendritic cells induce efficient stimulation of antiviral immunity in the context of chronic hepatitis B virus infection , 2012, Hepatology.

[10]  Paul J Rider,et al.  A liver‐specific microRNA binds to a highly conserved RNA sequence of hepatitis B virus and negatively regulates viral gene expression and replication , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  Jianguo Wu,et al.  Hepatitis B Virus Induces a Novel Inflammation Network Involving Three Inflammatory Factors, IL-29, IL-8, and Cyclooxygenase-2 , 2011, The Journal of Immunology.

[12]  S. Locarnini,et al.  The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway. , 2011, Journal of hepatology.

[13]  C. Schindler,et al.  Suppressor of Cytokine Signaling (SOCS) 1 Inhibits Type I Interferon (IFN) Signaling via the Interferon α Receptor (IFNAR1)-associated Tyrosine Kinase Tyk2* , 2011, The Journal of Biological Chemistry.

[14]  Ying Zhu,et al.  Interference of replication between hepatitis B and C viruses in patients infected with HIV , 2011, Journal of medical virology.

[15]  D. Brooks,et al.  The role of IL-10 in regulating immunity to persistent viral infections. , 2011, Current topics in microbiology and immunology.

[16]  R. Perrillo.  Benefits and risks of interferon therapy for hepatitis B , 2009, Hepatology.

[17]  Dongliang Yang,et al.  Hepatitis B virus suppresses toll‐like receptor–mediated innate immune responses in murine parenchymal and nonparenchymal liver cells , 2009, Hepatology.

[18]  P. Lei,et al.  HBx protein induces expression of MIG and increases migration of leukocytes through activation of NF-kappaB. , 2009, Virology.

[19]  J. Tavernier,et al.  The many faces of the SOCS box. , 2008, Cytokine & growth factor reviews.

[20]  S. Maher,et al.  IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. , 2008, Cancer biology & therapy.

[21]  Xiaonan Zhang,et al.  Hepatitis B virus polymerase inhibits the interferon-inducible MyD88 promoter by blocking nuclear translocation of Stat1. , 2007, The Journal of general virology.

[22]  Graham R. Foster,et al.  Interferons at age 50: past, current and future impact on biomedicine , 2007, Nature Reviews Drug Discovery.

[23]  S. Kotenko,et al.  Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells. , 2007, Virus research.

[24]  Masato Kubo,et al.  SOCS proteins, cytokine signalling and immune regulation , 2007, Nature Reviews Immunology.

[25]  S. Lewin,et al.  Regulation of Toll‐like receptor‐2 expression in chronic hepatitis B by the precore protein , 2007, Hepatology.

[26]  Charles M. Rice,et al.  Interferons α and λ Inhibit Hepatitis C Virus Replication With Distinct Signal Transduction and Gene Regulation Kinetics , 2006 .

[27]  Pallavur Sivakumar,et al.  Interleukin‐29 uses a type 1 interferon‐like program to promote antiviral responses in human hepatocytes , 2006, Hepatology.

[28]  S. Riordan,et al.  Reduced Expression of Toll-Like Receptor 2 on Peripheral Monocytes in Patients with Chronic Hepatitis B , 2006, Clinical and Vaccine Immunology.

[29]  C. Rice,et al.  Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. , 2006, Gastroenterology.

[30]  L. Platanias.  Mechanisms of type-I- and type-II-interferon-mediated signalling , 2005, Nature Reviews Immunology.

[31]  F. Chisari,et al.  Lambda Interferon Inhibits Hepatitis B and C Virus Replication , 2005, Journal of Virology.

[32]  B. Rehermann,et al.  Immunology of hepatitis B virus and hepatitis C virus infection , 2005, Nature Reviews Immunology.

[33]  G. Stark,et al.  Role of Tyrosine 441 of Interferon-γ Receptor Subunit 1 in SOCS-1-mediated Attenuation of STAT1 Activation* , 2005, Journal of Biological Chemistry.

[34]  S. Marras,et al.  Development of a Molecular-Beacon Assay To Detect the G1896A Precore Mutation in Hepatitis B Virus-Infected Individuals , 2005, Journal of Clinical Microbiology.

[35]  D. Ganem,et al.  Hepatitis B virus infection--natural history and clinical consequences. , 2004, The New England journal of medicine.

[36]  R. Purcell,et al.  Genomic analysis of the host response to hepatitis B virus infection. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[37]  D. Milich,et al.  Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection , 2003, Hepatology.

[38]  A. Lewis-Antes,et al.  IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. , 2003, Nature immunology.

[39]  Y. Ilan.  Immune downregulation leads to upregulation of an antiviral response: a lesson from the hepatitis B virus. , 2002, Microbes and infection.

[40]  Scott R. Presnell,et al.  IL-28, IL-29 and their class II cytokine receptor IL-28R , 2002, Nature Immunology.

[41]  C. Samuel,et al.  Antiviral Actions of Interferons , 2001, Clinical Microbiology Reviews.

[42]  D. Levy,et al.  The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion. , 2001, Cytokine & growth factor reviews.

[43]  W. Hop,et al.  Interferon‐alpha therapy for chronic hepatitis B: Early response related to pre‐treatment changes in viral replication , 2001, Journal of medical virology.

[44]  J. G. Zhang,et al.  Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[45]  C. Seeger,et al.  Hepatitis B Virus Biology , 2000, Microbiology and Molecular Biology Reviews.

[46]  M. Shapiro,et al.  Viral clearance without destruction of infected cells during acute HBV infection. , 1999, Science.

[47]  K. Shuai,et al.  The Suppressor of Cytokine Signaling (SOCS) 1 and SOCS3 but Not SOCS2 Proteins Inhibit Interferon-mediated Antiviral and Antiproliferative Activities* , 1998, The Journal of Biological Chemistry.

[48]  M. Chen,et al.  The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence. , 1998, Journal of immunology.

[49]  J. Quinn,et al.  Transmission of a homogenous hepatitis B virus population of A1896‐containing strains leading to mild resolving acute hepatitis and seroconversion to hepatitis B e antigen antibodies in an adult , 1997, Hepatology.

[50]  Warren S. Alexander,et al.  A family of cytokine-inducible inhibitors of signalling , 1997, Nature.

[51]  F. Schödel,et al.  The hepatitis B virus core and e antigens elicit different Th cell subsets: antigen structure can affect Th cell phenotype , 1997, Journal of virology.

[52]  D. Häussinger,et al.  Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. , 1996, The New England journal of medicine.

[53]  F. Zoulim,et al.  Analysis of hepatitis B virus genotypes and pre‐core region variability during interferon treatment of HBe antigen negative chronic hepatitis B , 1996, Journal of medical virology.

[54]  H. Tsubouchi,et al.  Interferon‐α2a for chronic hepatitis B with e antigen or antibody: comparable antiviral effects on wild‐type virus and precore mutant , 1995, Journal of viral hepatitis.

[55]  M. Brunetto,et al.  Treatment of chronic anti-HBe-positive hepatitis B with interferon-alpha. , 1995, Journal of hepatology.

[56]  B. Cohen,et al.  The human interferon alpha/beta receptor: characterization and molecular cloning. , 1994, Cell.

[57]  M. Brunetto,et al.  Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. , 1993, Gastroenterology.

[58]  M. Rugge,et al.  A randomized controlled trial of lymphoblastoid interferon‐α in patients with chronic hepatitis B lacking HBeAg , 1992, Hepatology.

[59]  M. Milella,et al.  Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon. , 1992, Journal of hepatology.

[60]  H. Thomas,et al.  Expression of the terminal protein region of hepatitis B virus inhibits cellular responses to interferons alpha and gamma and double-stranded RNA. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[61]  H. Thomas,et al.  Treatment of hepatitis B virus infection with interferon. Factors predicting response to interferon. , 1991, Journal of hepatology.

[62]  E. Schiff,et al.  A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis B , 1990 .

[63]  F Tsuda,et al.  Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen , 1990, Journal of virology.

[64]  E. Schiff,et al.  A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. , 1990, The New England journal of medicine.

[65]  H. Thomas,et al.  MUTATION PREVENTING FORMATION OF HEPATITIS B e ANTIGEN IN PATIENTS WITH CHRONIC HEPATITIS B INFECTION , 1989, The Lancet.

[66]  M. Brunetto,et al.  Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen , 1989, Hepatology.

[67]  J. Harris,et al.  Randomised controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response. , 1989, Gut.

[68]  H. Varmus,et al.  Expression of the precore region of an avian hepatitis B virus is not required for viral replication , 1987, Journal of virology.

[69]  G. Vyas,et al.  Biology of hepatitis B virus. , 1981, Science.

[70]  M. Rugge,et al.  Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection. , 1980, Gastroenterology.

[71]  B. Schwartz.  Letter: Ondine's curse. , 1976, Lancet.